Ajanta Pharma Ltd

BSE: 532331

31

total announcements

AJANTPHARM.BO · 15 min delayed

Key Stats · Yahoo Finance · as of 11 Nov 2026

Market Cap

₹41,744 Cr

P/E (TTM)

41.2

P/E (Forward)

33.6

EPS (TTM)

₹81.11

52W Low

₹2,022.05

52W High

₹3,409.50

Dividend Yield

1.98%

Beta

0.16

Price / Book

9.7

Debt / Equity

5.7

Revenue (TTM)

₹5,202 Cr

Gross Margin

76.27%

Operating Margin

24.64%

BSEInsider Trading / SASTPledge2d ago

Ajanta Pharma Ltd

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 09, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust

Ajanta Pharma Ltd's promoter Aayush Agrawal has created and released pledges on shares totaling 11,25,000 and 10,25,000 respectively, with reasons for creation being a new loan and top-up call, and reasons for release being loan closure.

Read more →📎 1 attachment
BSECompany UpdateResults4 Nov 2026

Ajanta Pharma Ltd

Pls find enclosed Earnings Call Written Transcript

Ajanta Pharma Ltd has uploaded the written transcript of its earnings call held on 30th October 2026 on its website, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults2 Nov 2026

Ajanta Pharma Ltd

Pls find enclosed newspaper publication of financial results for the quarter ended 30.09.2026.

Ajanta Pharma Ltd has published its unaudited financial results for the quarter and half-year ended September 30, 2026, showing a net profit of Rs. 439.02 lakhs and Rs. 936.81 lakhs respectively. The company's total income from operations for the quarter and half-year ended September 30, 2026, was Rs. 11,665.88 lakhs and Rs. 23,424.27 lakhs respectively.

Read more →📎 1 attachment
BSECompany UpdateResults30 Oct 2026

Ajanta Pharma Ltd

Pls find enclosed Audio recording of Earnings Call

Ajanta Pharma Ltd has uploaded the audio recording of its earnings call held on 30th October 2026, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The recording is available on the company's website.

Read more →📎 1 attachment
BSEInsider Trading / SASTRegulatory21 Oct 2026

Ajanta Pharma Ltd

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust

Ajanta Pharma Ltd received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust.

Read more →📎 1 attachment
BSEBoard MeetingResults15 Oct 2026

Ajanta Pharma Ltd

Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve Unaudited consolidated and standalone financial results of the Company for the second quarter and half year ended 30th September 2026

Ajanta Pharma Ltd has scheduled a board meeting on 30/10/2026 to consider and approve unaudited consolidated and standalone financial results for the second quarter and half year ended 30th September 2026.

Read more →📎 1 attachment
BSEInsider Trading / SAST25 Sept 2026

Ajanta Pharma Ltd

Pls find enclosed herewith closure of trading window intimation

Ajanta Pharma Ltd has announced the closure of its trading window for dealing in securities from October 1, 2026, until 48 hours after the declaration of its second-quarter and half-year financial results for the period ended September 30, 2026.

Read more →📎 1 attachment
BSECompany Update31 Aug 2026

Ajanta Pharma Ltd

Pls find enclosed Intimation w.r.t Participation in Investor Conference.

Ajanta Pharma Ltd has announced its participation in two investor conferences on September 16 and 28, 2026, with Jefferies India Forum and PL Capital Mid & Small Cap Conference, respectively. The meetings will be held at Oberoi, New Delhi, and Trident, BKC, Mumbai. The company confirms that the discussions will be based on already published information.

Read more →📎 1 attachment
BSEInsider Trading / SASTPledge27 Aug 2026

Ajanta Pharma Ltd

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 27, 2026 for Aayush Agrawal, trustee ....

Ajanta Pharma Ltd has received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a significant acquisition of shares by Aayush Agrawal, trustee, and other related parties.

Read more →📎 1 attachment
Page 1 of 2Next →